The central risk is that UiPath proves useful in agentic AI but not uniquely valuable. If customers treat
orchestration, governance, and testing as features inside broader suites, revenue can still grow modestly while pricing power and terminal multiple stay capped. The near-term gating items are commercial proof from packaged solutions, partner-led deployments, and clean FY2027 execution against guided
ARR and revenue targets.